CoChat

Effect of linaclotide in irritable bowel syndrome with constipation (IBS‐C): a systematic review and meta‐analysis

Atluri, D. K., Chandar, A. K., Bharucha, A. E., Falck‐Ytter, Y. · 2014 · Neurogastroenterology & Motility
Cited by 68

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: Treatment options for constipation‐predominant irritable bowel syndrome (IBS‐C) are limited. While linaclotide improved IBS‐C symptoms in randomized controlled trials (RCT s), results vary among studies and the magnitude of benefit is unclear. Methods: Two investigators independently extracted data on study participants, methods and outcomes (i.e., symptoms, quality of life, and adverse events) from eligible articles i.e., RCT s comparing linaclotide with placebo in adult patients with IBS‐C with a follow‐up of 12 weeks or longer. The grading of recommendations assessment, development and evaluation (GRADE) methodology was used to rate the quality of evidence. Key Results: Of 182 identified citations, three RCT s enrolling 1773 patients met the inclusion criteria. Compared with placebo, fewer patients on linaclotide failed to achieve responses i.e., FDA endpoint (1604 patients, risk ratio [RR] = 0.80; 95%CI 0.76–0.85), adequate IBS symptom relief (1773 patients, RR = 0.73; 95%CI 0.65–0.82), and clinically meaningful improvement in IBS‐QOL (1659 patients, RR = 0.78; 95%CI 0.72–0.86). The incidence of diarrhea leading to discontinuation of treatment was higher for linaclotide (1773 patients, RR = 14.75; 95%CI 4.04–53.81). The quality of evidence was rated as moderate for FDA endpoint and adequate relief response, high for diarrhea, and low for IBS‐QOL. Generalizability may be limited by the study population (i.e., predominantly white female patients), lack of data regarding prior therapy, and availability of few RCT s. The number of patients is insufficient to identify rare adverse events. Conclusions & Inferences: Linaclotide is moderately effective in improving symptoms of IBS‐C with diarrhea being the major side effect. Further studies are needed to evaluate the long‐term efficacy and safety of linaclotide for IBS‐C.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/nmo.12292

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 68

Metadata

Authors
Atluri, D. K., Chandar, A. K., Bharucha, A. E., & Falck‐Ytter, Y.
Venue
Neurogastroenterology & Motility
Publisher
Wiley
Published
2013-12-18
Volume
26
Issue
4
Pages
499-509
ISSN
  • 1350-1925 (ISSN-L)
  • 1365-2982
OpenAlex
W2087847277
Cited by
68
References
8
FWCI
0.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of linaclotide in irritable bowel syndrome with constipation (IBS‐C): a systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/nmo.12292
The paper
Atluri, D. K., Chandar, A. K., Bharucha, A. E., & Falck‐Ytter, Y. (2014). Effect of linaclotide in irritable bowel syndrome with constipation (IBS‐C): a systematic review and meta‐analysis. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.12292

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.